Evaluating the Glucantime Concentration for the ex vivo Glial Cell Model of Antimony-resistant Leishmania tropica Amastigotes
Yıl: 2021 Cilt: 45 Sayı: 4 Sayfa Aralığı: 237 - 240 Metin Dili: İngilizce DOI: 10.4274/tpd.galenos.2021.57966 İndeks Tarihi: 25-05-2022
Evaluating the Glucantime Concentration for the ex vivo Glial Cell Model of Antimony-resistant Leishmania tropica Amastigotes
Öz: Objective: Because the protocols used in the treatment of leishmaniasis can be toxic and have many limitations, such as the
development of resistance against such protocols, new treatment options are needed, especially against resistant patients. Ex vivo
models may be a good source for evaluating new drug options for patients with antimony-resistant parasites. This study aimed to
evaluate the Glucantime concentration for our ex vivo glial cell amastigote model we had defined in previous work.
Methods: We prepared the astroglial cell culture from brains of 2 to 3 day old neonatal Sprague-Dawley rats under sterile
conditions by modifying McCarthy’s method. Four plates of cells were infected with antimony-resistant Leishmania tropica
promastigotes. After 24 h of incubation, we added Glucantime to 3 plates with different concentrations. After 72 h, we removed
the supernatant and then dried, fixed, and stained the plates with Giemsa to count the amastigotes in the glial cells.
Results: We observed the amastigotes in glial cells in the control flask. Glial cells were ruined in flasks, which include 75 µg/
mL and 37.5 µg/mL Glucantime. The number of amastigotes per 100 glial cells was 116 for the flask with 7.5 µg/mL Glucantime
concentration, while 487 for the control flask.
Conclusion: We found that while high concentrations of Glucantime were toxic for glial cells, 7.5 µg/mL Glucantime concentration
managed to reduce the number of Leishmania tropica amastigotes in glial cells.
Anahtar Kelime: Antimon Dirençli Leishmania tropica Amastigotlarının ex vivo Glial HücreModeli için Glukantim Konsantrasyonunun Değerlendirilmesi
Öz: Amaç: Leishmaniasis tedavisinde kullanılan ilaçlar toksiktir ve pratikte uygulanan tedavi protokollerine karşı direnç gelişimi gibi
birçok kısıtlılığı vardır. Özellikle dirençli hastalar için yeni tedavi seçeneklerine ihtiyaç vardır. Ex vivo modeller, antimon direnci
olan hastalarda yeni ilaç seçeneklerini değerlendirmek için iyi bir kaynak olabilir. Bu çalışmada, daha önce tanımladığımız ex vivo
glial hücre amastigot modelimizde kullanılabilecek Glukantim konsantrasyonunu değerlendirmeyi amaçladık.
Yöntemler: Astroglial hücre kültürü, McCarthy’nin yöntemi değiştirilerek steril koşullar altında 2-3 günlük yenidoğan SpragueDawley sıçan beyinlerinden hazırlandı. Dört hücre plağı antimon dirençli Leishmania tropica promastigotları ile enfekte edildi.
Yirmi dört saatlik inkübasyondan sonra Glukantim farklı konsantrasyonlarda üç plakaya eklendi. Yetmiş iki saat sonra üst sıvı
çıkarıldı, plaklar kurutuldu, sabitlendi ve glial hücrelerdeki amastigotları saymak için Giemsa ile boyandı.
Bulgular: Amastigotlar, kontrol plağındaki glial hücrelerde yoğun şekilde gözlendi. 75 µg/mL ve 37,5 µg/mL Glukantim içeren
şişelerde glial hücreler tamamen hasarlandı. Yüz glial hücre başına amastigot sayısı, 7,5 µg/mL Glukantim konsantrasyonlu plak
için 116 iken kontrol plağı için 487 idi.
Sonuç: Yüksek Glukantim konsantrasyonları glial hücreler için toksik bulundu ve 7,5 µg/mL Glukantim konsantrasyonu glial
hücrelerdeki Leishmania tropica amastigotlarının sayısını azaltmak için yeterli bulundu.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Ghatee MA, Taylor WR, Karamian M. The Geographical Distribution of Cutaneous Leishmaniasis Causative Agents in Iran and Its Neighboring Countries, A Review. Front Public Health 2020; 8: 11.
- 2. Oryan A, Akbari M. Worldwide risk factors in leishmaniasis. Asian Pac J Trop Med 2016; 9: 925-32.
- 3. Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet 2018; 392: 951-70.
- 4. Savoia D. Recent updates and perspectives on leishmaniasis. J Infect Dev Ctries 2015; 9: 588-96.
- 5. Copeland NK, Aronson NE. Leishmaniasis: treatment updates and clinical practice guidelines review. Curr Opin Infect Dis 2015; 28: 426-37.
- 6. Berman JD, Chulay JD, Hendricks LD, Oster CN. Susceptibility of clinically sensitive and resistant Leishmania to pentavalent antimony in vitro. Am J Trop Med Hyg 1982; 31: 459-65.
- 7. Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med 2006; 3: e162.
- 8. Croft SL. Monitoring drug resistance in leishmaniasis. Trop Med Int Health 2001; 6: 899-905.
- 9. Soleimanifard S, Arjmand R, Saberi S, Salehi M, Hejazi SH. Treatment Outcome of the Drug-resistant Zoonotic Cutaneous Leishmaniasis by Glucantime. Adv Biomed Res 2017; 6: 17.
- 10. Zorbozan O, Harman M, Evren V, Erdoğan MA, Kılavuz A, Tunalı V, et al. Glia hücrelerinin antimona dirençli Leishmania tropica ile enfekte edilmesi: Yeni bir ex-vivo modeli [Infecting glial cells with antimony resistant Leishmania tropica: A new ex-vivo model]. Mikrobiyol Bul 2018; 52: 49-55.
- 11. McCarthy KD, de Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 1980; 85: 890-902.
- 12. Yilmaz ÖA, Taşkıran D, Aydar S. Cytotoxicity in cytokine stimulated astrocyte cultures: role of IL-6 and nitric oxide. Neurosci Res Commun 2004; 34: 82-91.
- 13. Zucca M, Scutera S, Savoia D. New chemotherapeutic strategies against malaria, leishmaniasis and trypanosomiases. Curr Med Chem 2013; 20: 502-26.
- 14. Le Pape P. Development of new antileishmanial drugs--current knowledge and future prospects. J Enzyme Inhib Med Chem 2008; 23: 708-18.
- 15. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000; 31: 1104-7.
- 16. Özbilgin A, Çavuş İ, Kaya T, Yıldırım A, Harman M. Comparison of in vitro Resistance of Wild Leishmania İsolates, Which are Resistant to Pentavalent Antimonial Compounds, Against Drugs Used in the Treatment of Leishmaniasis. Turkiye Parazitol Derg 2020; 44: 12-6.
- 17. Özbilgin A, Çavuş İ, Yıldırım A, Kaya T, Ertabaklar H. Evaluation of In vitro and In vivo Drug Efficacy Over Leishmania tropica: A Pilot Study. Turkiye Parazitol Derg 2018; 42: 11-9.
- 18. Güler E, Özbilgin A, Çavuş İ, Baddal B, Etikan İ, Başer KHC, et al. In vitro Anti-Leishmanial Activity of Essential Oils Extracted from Plants Growing in Northern Cyprus Against Leishmania tropica. Turkiye Parazitol Derg 2021; 45: 101-7.
- 19. Loeuillet C, Bañuls AL, Hide M. Study of Leishmania pathogenesis in mice: experimental considerations. Parasit Vectors 2016; 9: 144.
- 20. Saduqi M, Sharifi I, Babaei Z, Keyhani A, Mostafavi M, Hakimi Parizi M, et al. Anti-Leishmanial and Immunomodulatory Effects of Epigallocatechin 3-O-Gallate on Leishmania tropica: Apoptosis and Gene Expression Profiling. Iran J Parasitol 2019; 14: 521-33.
APA | Zorbozan O, EVREN V, HARMAN M, Ozbilgin A, A Yilmaz O, TURGAY N (2021). Evaluating the Glucantime Concentration for the ex vivo Glial Cell Model of Antimony-resistant Leishmania tropica Amastigotes. , 237 - 240. 10.4274/tpd.galenos.2021.57966 |
Chicago | Zorbozan Orçun,EVREN VEDAT,HARMAN MEHMET,Ozbilgin Ahmet,A Yilmaz Ozlem,TURGAY NEVIN Evaluating the Glucantime Concentration for the ex vivo Glial Cell Model of Antimony-resistant Leishmania tropica Amastigotes. (2021): 237 - 240. 10.4274/tpd.galenos.2021.57966 |
MLA | Zorbozan Orçun,EVREN VEDAT,HARMAN MEHMET,Ozbilgin Ahmet,A Yilmaz Ozlem,TURGAY NEVIN Evaluating the Glucantime Concentration for the ex vivo Glial Cell Model of Antimony-resistant Leishmania tropica Amastigotes. , 2021, ss.237 - 240. 10.4274/tpd.galenos.2021.57966 |
AMA | Zorbozan O,EVREN V,HARMAN M,Ozbilgin A,A Yilmaz O,TURGAY N Evaluating the Glucantime Concentration for the ex vivo Glial Cell Model of Antimony-resistant Leishmania tropica Amastigotes. . 2021; 237 - 240. 10.4274/tpd.galenos.2021.57966 |
Vancouver | Zorbozan O,EVREN V,HARMAN M,Ozbilgin A,A Yilmaz O,TURGAY N Evaluating the Glucantime Concentration for the ex vivo Glial Cell Model of Antimony-resistant Leishmania tropica Amastigotes. . 2021; 237 - 240. 10.4274/tpd.galenos.2021.57966 |
IEEE | Zorbozan O,EVREN V,HARMAN M,Ozbilgin A,A Yilmaz O,TURGAY N "Evaluating the Glucantime Concentration for the ex vivo Glial Cell Model of Antimony-resistant Leishmania tropica Amastigotes." , ss.237 - 240, 2021. 10.4274/tpd.galenos.2021.57966 |
ISNAD | Zorbozan, Orçun vd. "Evaluating the Glucantime Concentration for the ex vivo Glial Cell Model of Antimony-resistant Leishmania tropica Amastigotes". (2021), 237-240. https://doi.org/10.4274/tpd.galenos.2021.57966 |
APA | Zorbozan O, EVREN V, HARMAN M, Ozbilgin A, A Yilmaz O, TURGAY N (2021). Evaluating the Glucantime Concentration for the ex vivo Glial Cell Model of Antimony-resistant Leishmania tropica Amastigotes. Türkiye Parazitoloji Dergisi, 45(4), 237 - 240. 10.4274/tpd.galenos.2021.57966 |
Chicago | Zorbozan Orçun,EVREN VEDAT,HARMAN MEHMET,Ozbilgin Ahmet,A Yilmaz Ozlem,TURGAY NEVIN Evaluating the Glucantime Concentration for the ex vivo Glial Cell Model of Antimony-resistant Leishmania tropica Amastigotes. Türkiye Parazitoloji Dergisi 45, no.4 (2021): 237 - 240. 10.4274/tpd.galenos.2021.57966 |
MLA | Zorbozan Orçun,EVREN VEDAT,HARMAN MEHMET,Ozbilgin Ahmet,A Yilmaz Ozlem,TURGAY NEVIN Evaluating the Glucantime Concentration for the ex vivo Glial Cell Model of Antimony-resistant Leishmania tropica Amastigotes. Türkiye Parazitoloji Dergisi, vol.45, no.4, 2021, ss.237 - 240. 10.4274/tpd.galenos.2021.57966 |
AMA | Zorbozan O,EVREN V,HARMAN M,Ozbilgin A,A Yilmaz O,TURGAY N Evaluating the Glucantime Concentration for the ex vivo Glial Cell Model of Antimony-resistant Leishmania tropica Amastigotes. Türkiye Parazitoloji Dergisi. 2021; 45(4): 237 - 240. 10.4274/tpd.galenos.2021.57966 |
Vancouver | Zorbozan O,EVREN V,HARMAN M,Ozbilgin A,A Yilmaz O,TURGAY N Evaluating the Glucantime Concentration for the ex vivo Glial Cell Model of Antimony-resistant Leishmania tropica Amastigotes. Türkiye Parazitoloji Dergisi. 2021; 45(4): 237 - 240. 10.4274/tpd.galenos.2021.57966 |
IEEE | Zorbozan O,EVREN V,HARMAN M,Ozbilgin A,A Yilmaz O,TURGAY N "Evaluating the Glucantime Concentration for the ex vivo Glial Cell Model of Antimony-resistant Leishmania tropica Amastigotes." Türkiye Parazitoloji Dergisi, 45, ss.237 - 240, 2021. 10.4274/tpd.galenos.2021.57966 |
ISNAD | Zorbozan, Orçun vd. "Evaluating the Glucantime Concentration for the ex vivo Glial Cell Model of Antimony-resistant Leishmania tropica Amastigotes". Türkiye Parazitoloji Dergisi 45/4 (2021), 237-240. https://doi.org/10.4274/tpd.galenos.2021.57966 |